Teladoc Health Sees Unusually Large Options Volume (NYSE:TDOC)

Teladoc Health, Inc. (NYSE:TDOC) was the target of unusually large options trading on Tuesday. Stock traders acquired 13,849 call options on the stock. This represents an increase of 99% compared to the average daily volume of 6,959 call options.

Insider Buying and Selling at Teladoc Health

In other news, CEO Charles III sold 17,805 shares of the business’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $6.10, for a total transaction of $108,610.50. Following the completion of the sale, the chief executive officer directly owned 465,535 shares of the company’s stock, valued at approximately $2,839,763.50. The trade was a 3.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 0.70% of the company’s stock.

Hedge Funds Weigh In On Teladoc Health

A number of large investors have recently bought and sold shares of the business. Renaissance Technologies LLC lifted its position in Teladoc Health by 1.3% during the 1st quarter. Renaissance Technologies LLC now owns 8,085,542 shares of the health services provider’s stock worth $44,066,000 after acquiring an additional 107,400 shares during the period. Monaco Asset Management SAM purchased a new position in Teladoc Health during the 2nd quarter worth approximately $26,864,000. Pale Fire Capital SE lifted its stake in Teladoc Health by 74.8% during the 1st quarter. Pale Fire Capital SE now owns 3,398,491 shares of the health services provider’s stock valued at $18,522,000 after acquiring an additional 1,454,288 shares during the period. Quantinno Capital Management LP lifted its stake in Teladoc Health by 128.0% during the 1st quarter. Quantinno Capital Management LP now owns 2,621,378 shares of the health services provider’s stock valued at $14,287,000 after acquiring an additional 1,471,631 shares during the period. Finally, Freestone Grove Partners LP acquired a new stake in Teladoc Health during the 2nd quarter valued at approximately $7,338,000. Institutional investors own 76.82% of the company’s stock.

Teladoc Health Stock Down 3.4%

Shares of NYSE TDOC opened at $5.79 on Thursday. The business has a fifty day simple moving average of $6.26 and a two-hundred day simple moving average of $6.88. The firm has a market cap of $1.05 billion, a PE ratio of -5.85 and a beta of 2.14. Teladoc Health has a twelve month low of $4.40 and a twelve month high of $9.89.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings data on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.04. Teladoc Health had a negative return on equity of 12.15% and a negative net margin of 7.13%. The firm had revenue of $606.93 million during the quarter, compared to the consensus estimate of $615.44 million. During the same period in the previous year, the company posted ($0.19) earnings per share. The firm’s quarterly revenue was down 4.0% on a year-over-year basis. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. On average, research analysts expect that Teladoc Health will post -0.92 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on TDOC. Canaccord Genuity Group decreased their price objective on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Citigroup dropped their target price on shares of Teladoc Health from $11.00 to $7.50 and set a “neutral” rating on the stock in a research note on Monday, August 3rd. Bank of America upped their target price on shares of Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teladoc Health in a research report on Wednesday, August 19th. Five equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Teladoc Health has a consensus rating of “Hold” and a consensus price target of $7.54.

Teladoc Health Company Profile

Teladoc Health, Inc (NYSE: TDOC) provides virtual healthcare services and technology that connect patients with physicians, therapists and other healthcare professionals. Its platform supports general medical care, specialist consultations, mental health services, chronic condition management and related healthcare programs through digital and remote-care channels.

The company’s offerings include Teladoc’s telehealth services, BetterHelp’s online counseling and therapy platform, and chronic care solutions developed through Livongo, which Teladoc acquired in 2020.